

Applicant : Ernest G. Hope  
Serial No. : 09/722,096  
Filed : November 22, 2000  
Page : 3

Attorney's Docket No.: 12531-002001

REMARKS


These amendments are made solely to amend the description of the figures to correspond with the formal drawings being filed herewith. No new matter is introduced.

Attached is a marked-up version of the changes being made by the current amendment.

Please apply any other charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: 19 OCT 2001

  
Anita E. Meiklejohn, Ph.D.  
Reg. No. 35,283

Fish & Richardson P.C.  
225 Franklin Street  
Boston, Massachusetts 02110-2804  
Telephone: (617) 542-5070  
Facsimile: (617) 542-8906

Applicant : Ernest G. Hope  
Serial No. : 09/722,096  
Filed : November 22, 2000  
Page : 4

Attorney's Docket No.: 12531-002001

RECEIVED  
JAN 22 2002  
TECH CENTER 1600/2900

Version with markings to show changes made

In the specification:

Paragraph beginning at page 9, line 8, has been amended as follows:

Figures 7A and 7B depict[s] Brefeldin A induced protection of EC from CIK mediated lysis. --

Paragraph beginning at page 31, line 2, has been amended as follows:

--Figures 7A and 7B illustrate[s] the results of an experiment demonstrating that brefeldin A (BFA; a compound which blocks transport of proteins from the golgi to the ER) protects EC from non-MHC I restricted killing. CIK targets were treated with BFA and/or tunicamycin (TM). Pre-treatment with BFA did not reduce killing of tumor or lymphoblastoid targets. However, it did suppress CIK mediated lysis of EC in a <sup>51</sup>Cr release assay (20:1 E:T ratio) with complete protection at 10  $\mu$ M BFA. This resistance is sustained after BFA is removed from the media. Resistant lymphoblastoid target AMK were rendered susceptible by a 22 hr TM pre-treatment that was not reversed by BFA treatment. Neither TM or TM and BFA together altered CIK mediated lysis of OCI-Ly8 tumor targets. --